Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/4/2025 | $28.00 | Outperform | Robert W. Baird |
11/18/2024 | $35.00 | Overweight | Stephens |
3/14/2024 | $27.00 | Buy | Citigroup |
3/7/2024 | $23.00 | Buy | BofA Securities |
12/21/2023 | $30.00 | Outperform | Oppenheimer |
8/24/2022 | $10.00 → $15.50 | Buy → Neutral | ROTH Capital |
2/8/2022 | $9.00 → $12.00 | Buy | HC Wainwright & Co. |
CORAL GABLES, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX) today announced the appointment of William (Will) T. Andrews, MD, FACP as Chief Medical Officer. Dr. Andrews will report directly to the Company's President and Chief Executive Officer, Richard J. Daly, and will serve as a member of the Company's executive leadership team. He succeeds Dr. Gary Ingenito, who is retiring after a successful career and will support the transition in a consulting capacity. "We are pleased to welcome Dr. Andrews to Catalyst. In addition to his foundational work in clinical practice in some of the country's most prestigious hospitals, he b
Catalyst Enters 2025 With Strong Momentum; Reiterates Confidence in Full-Year Outlook Delivers Record Q1 2025 Total Revenues of $141.4 Million, a 43.6% YoY Increase FIRDAPSE® and AGAMREE® Drive Sustained Organic Growth, Underscoring Execution Strength Reaffirms Full-Year 2025 Total Revenue Guidance Provided Earlier This Year of Between $545 Million and $565 MillionStrengthens Balance Sheet with Cash and Cash Equivalents of $580.7 Million and No Debt as of March 31, 2025 Conference Call and Webcast to be Held on May 8, 2025, at 8:30 AM ET CORAL GABLES, Fla., May 07, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), today reported f
CORAL GABLES, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate at the upcoming BofA Securities Health Care Conference 2025 on Wednesday, May 14, 2025, at the Encore Hotel, Las Vegas, Nevada. Presentation Details:Date: Wednesday, May 14, 2025Time: 8:00 am PTWebcast Link The webcast will be ava
4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
3 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)